Stem Cell Therapy for Vitiligo

What This Article Covers

Vitiligo is an autoimmune skin condition in which the body's immune system destroys melanocytes, the pigment-producing cells in skin. Over the past two decades, researchers have developed cell-transplant techniques — often loosely grouped under “stem cell” or “regenerative” approaches — that harvest a patient's own healthy pigment cells and relocate them to depigmented patches. This article covers what these techniques are, the clinical evidence behind them (including one FDA-approved device), and who is typically eligible.

Unlike many regenerative therapies still confined to early trials, autologous skin cell transplantation for vitiligo has reached a genuine regulatory milestone in the United States, alongside a longer track record of surgical melanocyte-transplant techniques used internationally. Emerging lab research on melanocyte stem cells points to where the field may go next.

How It's Thought to Work

Vitiligo destroys the melanocytes living in the outer skin layer, but reservoirs of melanocyte precursor cells often persist in hair follicles and in pigmented skin elsewhere on the body. Cell-transplant techniques exploit this by harvesting a thin sample of a patient's own healthy, pigmented skin, processing it (either as a “non-cultured” cell suspension prepared at the point of care, or as melanocytes expanded in a lab over several weeks), and applying the resulting cell suspension to a depigmented area that has first been prepared — typically by superficial laser resurfacing or dermabrasion — to receive it. The transplanted melanocytes and keratinocytes then, in successful cases, repopulate the treated area and gradually restore color. This is fundamentally different from systemic stem cell infusions used in other conditions; it is a localized, autologous (self-to-self) cell graft rather than a stem cell “treatment” delivered by injection or IV.

What the Evidence Shows

The strongest evidence to date supports the RECELL Autologous Cell Harvesting System, which received FDA premarket approval in June 2023 specifically for repigmentation of stable depigmented vitiligo lesions in adults — the first FDA-approved device-based therapy of its kind for vitiligo (FDA, 2023). In the pivotal within-patient trial, treated areas achieved markedly better results than areas receiving standard narrowband UVB phototherapy alone: 56% of RECELL-treated sites reached over 50% repigmentation at 6 months versus just 12% of control sites, and 36% reached 80% or greater repigmentation versus 0% of controls — with successful results largely maintained at 12 months (Journal of the American Academy of Dermatology, 2024). Those are encouraging numbers for a condition with historically limited treatment options, though it's worth noting results varied widely between patients and a meaningful share of treated areas did not reach substantial repigmentation.

Outside the U.S., surgical non-cultured melanocyte-keratinocyte transplantation has a longer history. A 2025 meta-analysis pooling 17 studies and nearly 1,200 patients found that both non-cultured and cultured melanocyte transplantation techniques produce meaningful repigmentation in stable vitiligo, with outcomes improving further when combined with phototherapy such as narrow-band UVB or excimer laser (P < 0.00001) — though the authors cautioned that study quality varied and called for better-designed randomized trials (Archives of Dermatological Research, 2025). A small long-term case series also found that repigmentation achieved through this transplant technique was largely sustained at six years of follow-up, suggesting results can be durable, not just short-lived (Journal of the European Academy of Dermatology and Venereology, 2019). Further upstream, preclinical research is exploring hair-follicle-derived melanocytes — which may resist the immune attack seen in vitiligo — as a future graft source; this work has so far been demonstrated only in mouse models, not humans (Stem Cell Research & Therapy, 2025).

Who Might Be a Candidate

• Adults with stable vitiligo — meaning no new lesions or spread for roughly 6–12 months, per most study protocols
• Patients with segmental or localized vitiligo patches that have not responded adequately to topical treatment or phototherapy alone
• Those without active Koebner phenomenon (new patches triggered by skin trauma), which can predict poor graft take
• Not typically appropriate for actively spreading (unstable) vitiligo, or as a first-line treatment before other options are tried

Bottom Line

Cell-transplant therapy for vitiligo — most notably the FDA-approved RECELL system — represents one of the more clinically validated regenerative approaches in dermatology today, with trial data showing real, sometimes durable repigmentation in stable disease. Even so, it is a specialized procedural treatment for stable, localized vitiligo, not a cure, and outcomes vary considerably between patients; it is not indicated for active, spreading disease. Anyone considering it should seek an experienced dermatologic surgeon and discuss realistic expectations, procedural risks, and how it fits alongside phototherapy and other standard treatments.